InsiderTrades.com logo
Grab This Altcoin Before Trump's Crypto Announcement
From Crypto 101 Media   |   Ad
Grab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which is why I'm recommending ONE coin to all investors right now.
Click here to check it out now
Jeffrey Stein net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Jeffrey Stein Biography and Net Worth

CEO of Cidara Therapeutics
Dr. Stein has been President, CEO and Director of Cidara since January 2014. Previously he was CEO of Trius Therapeutics, Inc. from 2007 until its acquisition by Cubist Pharmaceuticals, Inc. in September 2013. During his tenure, Trius developed the antibacterial drug tedizolid, which received marketing approval from the U.S. Food and Drug Administration in June 2014. Tedizolid is now marketed by Merck under the name Sivextro. Dr. Stein currently serves as a Director of Paratek Pharmaceuticals (NASDAQ: PRTK) and Ideaya Biosciences. He is also founding Chairman and President of the Antimicrobials Working Group, an industry leading 501(c)(6) organization. Previously, Dr. Stein was a Venture Partner and Kauffman Fellow with Sofinnova Ventures and opened the firm’s San Diego office in 2005. Prior to joining Sofinnova Ventures, Dr. Stein was co-founder and Chief Scientific Officer of Quorex Pharmaceuticals, which was acquired by Pfizer Pharmaceuticals in 2005. He has also served as a Principal Scientist with Diversa Corporation and the Agouron Institute. Dr. Stein conducted his postdoctoral research as an Alexander Hollaender Distinguished Postdoctoral Fellow at the California Institute of Technology and his graduate work as a NASA Graduate Student Researcher Fellow at the University of California, San Diego.

What is Jeffrey Stein's net worth?

The estimated net worth of Jeffrey Stein is at least $570,747.60 as of June 7th, 2024. Dr. Stein owns 24,580 shares of Cidara Therapeutics stock worth more than $570,748 as of December 26th. This net worth evaluation does not reflect any other investments that Dr. Stein may own. Additionally, Dr. Stein receives a salary of $603,700.00 as CEO at Cidara Therapeutics. Learn More about Jeffrey Stein's net worth.

How old is Jeffrey Stein?

Dr. Stein is currently 69 years old. There are 5 older executives and no younger executives at Cidara Therapeutics. Learn More on Jeffrey Stein's age.

What is Jeffrey Stein's salary?

As the CEO of Cidara Therapeutics, Inc., Dr. Stein earns $603,700.00 per year. The highest earning executive at Cidara Therapeutics is Dr. Leslie Tari Ph.D., Chief Scientific Officer, who commands a salary of $845,100.00 per year. Learn More on Jeffrey Stein's salary.

How do I contact Jeffrey Stein?

The corporate mailing address for Dr. Stein and other Cidara Therapeutics executives is 6310 NANCY RIDGE DRIVE SUITE 101, SAN DIEGO CA, 92121. Cidara Therapeutics can also be reached via phone at (858) 752-6170 and via email at [email protected]. Learn More on Jeffrey Stein's contact information.

Has Jeffrey Stein been buying or selling shares of Cidara Therapeutics?

Jeffrey Stein has not been actively trading shares of Cidara Therapeutics during the last ninety days. Most recently, on Friday, June 7th, Jeffrey Stein bought 8,000 shares of Cidara Therapeutics stock. The stock was acquired at an average cost of $13.21 per share, with a total value of $105,680.00. Following the completion of the transaction, the chief executive officer now directly owns 24,580 shares of the company's stock, valued at $324,701.80. Learn More on Jeffrey Stein's trading history.

Who are Cidara Therapeutics' active insiders?

Cidara Therapeutics' insider roster includes Neil Abdollahian (Insider), Paul Daruwala (COO), Timothy Franson (Director), Brady Johnson (VP), Jessica Oien (General Counsel), Preetam Shah (CFO), Jeffrey Stein (CEO), and Leslie Tari (Insider). Learn More on Cidara Therapeutics' active insiders.

Are insiders buying or selling shares of Cidara Therapeutics?

In the last twelve months, Cidara Therapeutics insiders bought shares 1 times. They purchased a total of 8,000 shares worth more than $105,680.00. In the last twelve months, insiders at the biotechnology company sold shares 4 times. They sold a total of 3,944 shares worth more than $51,223.36. The most recent insider tranaction occured on September, 11th when insider Taylor Sandison sold 924 shares worth more than $10,755.36. Insiders at Cidara Therapeutics own 7.6% of the company. Learn More about insider trades at Cidara Therapeutics.

Information on this page was last updated on 9/11/2024.

Jeffrey Stein Insider Trading History at Cidara Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/7/2024Buy8,000$13.21$105,680.0024,580View SEC Filing Icon  
8/8/2023Buy2,500$19.20$48,000.0016,580View SEC Filing Icon  
3/27/2023Buy2,500$20.80$52,000.0014,080View SEC Filing Icon  
11/12/2021Buy2,500$31.80$79,500.00View SEC Filing Icon  
8/18/2021Buy2,000$34.40$68,800.00View SEC Filing Icon  
9/24/2019Buy2,625$38.20$100,275.0014,116View SEC Filing Icon  
5/23/2018Buy10,638$94.00$999,972.00View SEC Filing Icon  
9/12/2017Buy367$135.80$49,838.602,592View SEC Filing Icon  
6/5/2017Buy750$119.00$89,250.00View SEC Filing Icon  
3/31/2017Buy645$155.00$99,975.00View SEC Filing Icon  
5/20/2016Buy215$230.20$49,493.00605View SEC Filing Icon  
11/25/2015Buy335$301.80$101,103.00335View SEC Filing Icon  
See Full Table

Jeffrey Stein Buying and Selling Activity at Cidara Therapeutics

This chart shows Jeffrey Stein's buying and selling at Cidara Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cidara Therapeutics Company Overview

Cidara Therapeutics logo
Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.
Read More

Today's Range

Now: $23.22
Low: $22.70
High: $23.42

50 Day Range

MA: $17.39
Low: $11.16
High: $23.73

2 Week Range

Now: $23.22
Low: $10.00
High: $24.99

Volume

49,538 shs

Average Volume

43,090 shs

Market Capitalization

$163.63 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.12
Grab This Altcoin Before Trump's Crypto Announcement
From Crypto 101 Media   |   Ad
Grab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which is why I'm recommending ONE coin to all investors right now.
Click here to check it out now